Randomized Trial of Targeted Indoor Spraying to Prevent Aedes-Borne Diseases.

Name: Αlpha¹ Rigor Record — Randomized Trial of Targeted Indoor Spraying to Prevent Aedes-Borne Diseases.
Item: Randomized Trial of Targeted Indoor Spraying to Prevent Aedes-Borne Diseases.
Rating: 96
Author: Αlpha¹

Dean NE, Crisp AM, Che-Mendoza A, Kirstein OD, Barrera-Fuentes GA, Earnest JT, Puerta-Guardo HN, Collins MH, Pavia-Ruz N, Ayora-Talavera G, González-Olvera G, Medina-Barreiro A, Bibiano-Marín W, Jabbarzadeh S, Halloran ME, Longini IM Jr, Lenhart A, Waller LA, Correa-Morales F, Palacio-Vargas J, Gomez-Dantes H, Manrique-Saide P, Vazquez-Prokopec GM

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.75★ (Adequate), 0 critical, 3 high issues for “Randomized Trial of Targeted Indoor Spraying to Prevent Aedes-Borne Diseases.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.75 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted cluster-randomized trial with rigorous design, clear reporting of methods, and appropriate ethical approvals. The main weakness is the absence of a data availability statement and code sharing, which is a notable gap for a clinical trial. Minor reporting issues include lack of explicit reporting guideline adherence and some copyedit errors.

Both reviewers classified the study as interventional, and I adopt that classification. The evaluation covered all eight dimensions; several sub-criteria were marked not applicable (e.g., cell line authentication, housing conditions) due to the human field trial nature. The statistics verification recomputed only a subset of tests (1 test), so the absence of errors does not confirm overall statistical correctness.

8 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites the growing public health impact of dengue, chikungunya, and Zika, and notes that classic control approaches have not succeeded. It references prior observational evidence for TIRS from Australia and mathematical models predicting its impact, and explicitly states the need for rigorous randomized trial evidence to inform policy. The limitations of prior work (observational design, reactive deployment) are acknowledged, and the trial is designed to address these gaps with a pre-seasonal, randomized design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on vector control, TIRS, and the need for randomized trials, and logically links this to the study objectives.

Evidence

paraphrase[Introduction, paragraph 1]

“The public health impact of Aedes-borne diseases (ABD), including chikungunya, dengue and Zika, is growing.”

direct quote[Introduction, paragraph 2]

“In Australia, TIRS deployed to houses during a dengue outbreak prevented up to 86% of cases.”